Significant association seen for patients referred for asthma/query asthma, but not those referred for other reasons
WEDNESDAY, March 12, 2025 (HealthDay News) — Patients are more likely to have positive bronchodilator responsiveness in the morning and in winter months, according to a study published online March 11 in Thorax.
Ben Knox-Brown, Ph.D., from the Royal Papworth Hospital NHS Foundation Trust in Cambridge, England, and colleagues examined the association between time of day and season of testing on the level of bronchodilator responsiveness in a population of 1,620 patients.
The researchers found that the odds of a positive bronchodilator response decreased by 8 percent per one-hour increment in the working day (odds ratio, 0.92). When time of day was dichotomized into morning and afternoon periods, a similar effect was seen, with reduced odds of responsiveness in the afternoon (odds ratio, 0.68). The impact of time of day was only seen in those referred for asthma/query asthma, while no association was seen for those referred for other reasons. Compared with the rest of the year, bronchodilator responsiveness was more common in winter months.
“These findings suggest that performing diagnostic testing when patients are most symptomatic, that is, in the morning, may improve diagnostic testing,” the authors write. “This also reinforces the need to document the timing of spirometry testing whenever possible, and that repeat testing should be done at the same time of day.”
One author disclosed financial ties to ndd Medical Technologies.
Fractional Exhaled Nitric Oxide Elevated in Pediatric Chest Tightness Variant Asthma
Higher Short-Term Exposure to Pollen Linked to Lower FEV1 in COPD
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders
Drug Retention in Spondyloarthritis Varies With Socioeconomic Status
Timing of JAK Initiation, Shingles Vaccine Administration Can Affect Outcomes in RA
Bimekizumab Well Tolerated, Efficacious Over Three Years in Axial Spondyloarthritis
Longer Persistence Seen With Upadacitinib Versus TNFi in Rheumatoid Arthritis
Achieving Low Serum Urate Levels Can Cut Risk for Cardiovascular Events in Gout